Page last updated: 2024-12-07

desmethylmianserin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Desmethylmianserin is a metabolite of the antidepressant mianserin. It exhibits anti-depressant activity and is believed to be a partial agonist of the 5-HT2A receptor. Research on desmethylmianserin focuses on its potential therapeutic applications, including its antidepressant effects and its role in the treatment of other conditions, such as anxiety and insomnia. Studies have also investigated its pharmacokinetic properties and its interactions with other drugs. The compound's importance lies in its potential to contribute to the development of novel therapeutic agents for various psychiatric disorders.'

Cross-References

ID SourceID
PubMed CID115194
CHEBI ID188043
SCHEMBL ID2739027
MeSH IDM0158507

Synonyms (28)

Synonym
desmethylmianserin
(+/-)-demethylmianserin
normianserine
demethylmianserin
1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
nor mianserin
2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
71936-92-0
CHEBI:188043
AKOS005216265
pi2h4adr4c ,
dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-
unii-pi2h4adr4c
1,2,3,4,10,14b-hexahydrodibenzo(c,f)pyrazino(1,2-a)azepine
org oh 46
FT-0673116
1,2,3,4,10,14b-hexahydrodibenzo[c,f]-pyrazino[1,2-a]azepine
SCHEMBL2739027
1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine #
n-desmethylmianserin
n-desmethyl mianserin
n-desmethyl ms
normianserin
DTXSID20891477
dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-
mfcd00871853
Q27286570
2,5-diazatetracyclo[13.4.0.0?,?.0?,??]nonadeca-1(19),8,10,12,15,17-hexaene

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In 44 depressed patients, subjective side effects during 3 weeks of treatment with 30 mg of mianserin were evaluated by the UKU Side Effect Rating Scale, and their relationships to plasma concentrations of mianserin and desmethylmianserin were analyzed."( Subjective side effects of mianserin in relation to plasma concentrations of mianserin and desmethylmianserin.
Fukushima, Y; Higuchi, H; Hishikawa, Y; Kaneko, S; Otani, K; Sasa, H, 1992
)
0.69

Dosage Studied

ExcerptRelevanceReference
"The relationships between the plasma concentrations of mianserin and desmethylmianserin at 18 h after initial dosing and those at steady state were studied in 19 depressed patients receiving 30 mg of mianserin at bedtime."( Prediction of plasma concentrations of mianserin and desmethylmianserin at steady state from those after an initial dose of mianserin.
Fukushima, Y; Kaneko, S; Mihara, K; Okada, M; Otani, K; Tanaka, O, 1993
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dibenzooxazepineAn organic heterotricyclic compound consisting of two benzene rings fused to a seven-membered ring containing one oxygen and one nitrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's10 (76.92)18.2507
2000's2 (15.38)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.55 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (7.14%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]